

Are you living with Parkinson's disease?

Learn more about the **ATLANTIS Study** today

If you've been diagnosed with Parkinson's disease at least 5 years ago and have daily motor symptom fluctuations, you may be able to join a research study of an investigational medication called UCB0022 given orally (by mouth) alongside your regular Parkinson's disease treatment.

The aim of this 18-weeks-long study is to find out more about an investigational drug called UCB0022 and assess its effectiveness, safety, tolerability, and pharmacokinetics (how the medication is processed in the body).

You may be able to join the ATLANTIS Study if you:

- Are between 35 and 80 years of age
- Have been diagnosed with Parkinson's disease 5 or more years ago
- Are experiencing daily motor fluctuations (at least 2 cumulative hours of "OFF" time every day when Parkinson's disease symptoms return after the medication has worn off)
- Are currently receiving treatment with levodopa (with or without additional therapies for Parkinson's disease)
- Are willing to complete a 3-day symptom diary at four time points during the study

You cannot participate in the study if you:

- Have had brain surgery for PD (including deep brain stimulation, thalamus surgery, and experimental cell therapy or gene therapy)
- Have a diagnosis of dementia, other forms of important cognitive dysfunction, epilepsy, Type 1 diabetes, uncontrolled Type 2 diabetes, or current untreated hypertension (high blood pressure)

There are additional criteria that need to be met to participate in the ATLANTIS Study, which the study team will discuss with you.

Travel reimbursement and travel support for participants and care partners is offered throughout the study and a stipend may also be paid.

Please contact us or visit atlantis-study.com to find out more:

Mike Stevenson
msteven1@bu.edu
(617) 638-7747



Please scan